Get started
Author

Ekaterina L. Serikova

Observed names: E. L. Serikova, E. Serikova, Ekaterina Serikova, Е.Л. Серикова, Серикова Екатерина Леонидовна
Observed institution: City Clinical Oncology Center
ORCID: 0000-0001-6933-0030
Observed ORCID: 0000-0001-6933-0030
OpenAlex ID: A5064195402
Clinical and morphological features of breast tumors with PIK3CA mutations in Russian patients: Observational study
2022 · Tatyana N. Sokolova, Tatyana I. Solov'eva, et al. · Journal of Modern Oncology · 3
PDF
Clinical and Morphological Features of ER-Positive HER2-Negative Breast Tumors with PIK3CA Mutations in Russian Patients
2025 · Tatyana N. Sokolova, Grigory A. Yanus, et al. · Cancers · 2
PDF
Results of the prospective randomized controlled trial VOG-01: Neoadjuvant endocrine therapy ribociclib + fulvestrant + GnRH-a versus chemotherapy 4 AC + 4 T for early HR+/HER2-negative breast cancer in premenopausal patients.
2025 · Rashida Orlova, Almira Vakhitova, et al. · Journal of Clinical Oncology · 1
PDF
34P Results of repeat core needle biopsies in ER+/HER2-negative breast cancer following neoadjuvant endocrine therapy with fulvestrant+triptorelin+ribociclib in premenopausal women
2025 · A. Vahitova, R.V. Orlova, et al. · Annals of Oncology
Tolerability of dose-dense and standard regimens of neoadjuvant chemotherapy in estrogen receptor-positive/HER2-negative breast cancer: results of a prospective observational study
2025 · R. V. Orlova, A. A. Vakhitova, et al. · Podderživaûŝaâ terapiâ v onkologii.
PDF
Works count: 8
Citation count: 6
H-index: 2
I10-index:
Year
Topic
Type